zinc finger protein 213Genealiases: CR53 · ZKSCAN21 · ZSCAN53
Q-omics provides the consensus-scored ZNF213 profile across patient tissues and cancer cell-line models. ZNF213 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ZNF213 is differentially expressed in 15, with the highest sampling consensus in KIRP. Additionally, ZNF213 RNA expression shows 19,540 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KIRP, and ACC as cancer lineages where ZNF213 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF213 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF213 survival associations across molecular data types. ZNF213 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF213 RNA expression–survival associations across cancer types. High ZNF213 expression shows unfavorable associations in LIHC and MESO, but favorable associations in UVM, HNSC, ACC and UCEC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ZNF213 RNA expression.
This table summarizes ZNF213 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRP for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF213. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF213 shows higher tumor expression in KIRP, LIHC, LUAD, HNSC, BRCA and STAD. The KIRP box plot shows higher ZNF213 RNA expression in tumor versus normal tissue (log2 FC = +1.110, t-test p < 0.001).
This table shows molecular features associated with ZNF213 in patient tissues and cancer cell lines. In patient samples, ZNF213 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF213 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
